- Home
- INR vs AVIR Comparison
INR vs AVIR Comparison
Compare INR & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INR
- AVIR
- Stock Information
- Founded
- INR 2017
- AVIR 2012
- Country
- INR United States
- AVIR United States
- Employees
- INR N/A
- AVIR N/A
- Industry
- INR
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- INR
- AVIR Health Care
- Exchange
- INR NYSE
- AVIR Nasdaq
- Market Cap
- INR 267.4M
- AVIR 273.7M
- IPO Year
- INR 2025
- AVIR 2020
- Fundamental
- Price
- INR $17.98
- AVIR $2.99
- Analyst Decision
- INR Strong Buy
- AVIR Hold
- Analyst Count
- INR 6
- AVIR 1
- Target Price
- INR $28.17
- AVIR $6.88
- AVG Volume (30 Days)
- INR 477.3K
- AVIR 274.5K
- Earning Date
- INR 01-01-0001
- AVIR 03-06-2025
- Dividend Yield
- INR N/A
- AVIR N/A
- EPS Growth
- INR N/A
- AVIR N/A
- EPS
- INR N/A
- AVIR N/A
- Revenue
- INR $259,022,000.00
- AVIR N/A
- Revenue This Year
- INR N/A
- AVIR N/A
- Revenue Next Year
- INR N/A
- AVIR N/A
- P/E Ratio
- INR $22.21
- AVIR N/A
- Revenue Growth
- INR 60.16
- AVIR N/A
- 52 Week Low
- INR $14.83
- AVIR $2.75
- 52 Week High
- INR $23.00
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- INR N/A
- AVIR 41.74
- Support Level
- INR N/A
- AVIR $2.90
- Resistance Level
- INR N/A
- AVIR $3.29
- Average True Range (ATR)
- INR 0.00
- AVIR 0.12
- MACD
- INR 0.00
- AVIR -0.01
- Stochastic Oscillator
- INR 0.00
- AVIR 17.95
About INR INFINITY NATURAL RESOURCES INC
Infinity Natural Resources Inc is an oil and natural gas exploration and production company. The group focused on developing unconventional reserves in Appalachia. It is engaged in acquiring, exploring, and developing properties for producing oil, natural gas, and natural gas liquids (NGLs) from underground reservoirs.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).